Aiforia Technologies Oy Class A
0.86
EUR
+0.00
(+0.12%)
ISIN
FI4000507934
Return %
Stock
S&P 500
1Y
-69.06
14.20
3Y
-73.62
81.12
5Y
- -
68.34
Capital Structure
EUR
•
in mil. unless spec.Working Capital
EUR
•
in mil. unless spec.Growth Rates
EUR
•
in mil. unless spec.Semi-annual Revenue
EUR
•
in mil. unless spec.Semi-annual Earnings Per Share
EUR
•
in mil. unless spec.Semi-annual Dividends Per Share
EUR
•
in mil. unless spec.Company Description
- CEO
- Jukka Pekka Tapaninen
- Full Time Employees
- 76
- Sector
- Technology services
- Industry
- Packaged software
- Address
- Helsinki Finland
- IPO Date
- Dec 10, 2021
- Website
- aiforia.com
- Similar Companies
- Business
- Aiforia Technologies Oyj is a Finland-based medical technology and software company that specializes in artificial intelligence (AI) and deep learning-based image analysis solutions for digital pathology, clinical diagnostics, and preclinical medical research. Founded in 2013 as a spin-off from the Institute for Molecular Medicine Finland at the University of Helsinki and headquartered in Helsinki, Finland, the company operates internationally across Europe, North America, and the Asia-Pacific region, maintaining a regional presence in Cambridge, Massachusetts, United States. Aiforia Technologies provides a cloud-based software-as-a-service (SaaS) platform designed to automate, standardize, and accelerate whole slide image analysis for pathologists, academic medical centers, pharmaceutical corporations, and contract research organizations (CROs). The company's core product and service portfolio includes Aiforia Create, a proprietary web-based software application enabling medical experts and researchers to train custom deep learning neural networks for tissue and cellular analysis without programming expertise; Aiforia Clinical Suite, a modular clinical diagnostic workflow platform featuring CE-IVD and CE-IVDR cleared AI models for oncology diagnostics, including automated grading, detection, and quantification tools for breast cancer biomarkers such as Ki-67, ER, PR, and HER2, prostate cancer Gleason grading, and lung cancer PD-L1 scoring; Aiforia Hub, a centralized image management and slide viewing system supporting telepathology, remote collaboration, and multi-site hospital workflows; Aiforia Community, a secure collaborative ecosystem for sharing pathology models, case data, and research insights; and specialized contract AI model development, validation, and preclinical image analysis services for drug discovery and translational science. In recent operational developments, Aiforia Technologies has expanded its global commercial footprint and digital ecosystem through strategic partnerships and integration agreements with enterprise digital pathology and laboratory information system providers, including Sectra and Tribun Health, alongside diagnostic workflow deployments across hospital networks and United Kingdom National Health Service (NHS) trusts. The company has also advanced its collaborative clinical validation initiatives with institutions such as the Mayo Clinic, expanded its CE-IVDR regulatory certifications in the European Union, introduced advanced foundation AI models to optimize algorithm development efficiency, and scaled its commercial operations across the North American biopharmaceutical and clinical laboratory markets.